Chen Dan, Wang Mei-Yi, Tian Chen
Department of Hematology, Hotan District People's Hospital, Hotan 848000, Xinjiang Uygur Autonomous Region, China.
Department of Haematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, Key Laboratory of Cancer Prevention and Therapy, 300060, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Apr;32(2):643-646. doi: 10.19746/j.cnki.issn.1009-2137.2024.02.049.
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a relatively inert B lymphocyte proliferative disease. In recent years with the launch of new drugs, chemotherapy has been gradually replaced by targeted therapy, which significantly prolongs the survival of patients and reduces the side effects of treatment. At present, BTK inhibitors, PI3K inhibitors, spleen tyrosine kinase (SYK) inhibitors and BCL-2 inhibitors are the most studied targeted therapeutic drugs for CLL/SLL. This article reviews the research progress of different types of targeted therapeutic drugs in the treatment of CLL/SLL.
慢性淋巴细胞白血病（CLL）/小淋巴细胞淋巴瘤（SLL）是一种相对惰性的B淋巴细胞增殖性疾病。近年来，随着新药的推出，化疗已逐渐被靶向治疗所取代，这显著延长了患者的生存期并减少了治疗的副作用。目前，布鲁顿酪氨酸激酶（BTK）抑制剂、磷脂酰肌醇-3激酶（PI3K）抑制剂、脾酪氨酸激酶（SYK）抑制剂和B细胞淋巴瘤-2（BCL-2）抑制剂是治疗CLL/SLL研究最多的靶向治疗药物。本文综述了不同类型靶向治疗药物在CLL/SLL治疗中的研究进展。
